Opportunities in pain therapy:beyond the opioids and NSAIDs

Bibliography

• LIPTON S: Pain mechanisms and management. Br. Med. Bull. (1991) 47 (3):i-iv.
   Google Scholar
• ERICKSON D: Progress against pain. Start-Up. Windhover's Review of Emerging Medical Ventures (2 April 1997):8–13.
   Google Scholar
• ••An exceeding well-written account of emerging targets in pain research with an especial focuson biotech company contributions.
   Google Scholar
• ENGBERG G, ORZEPOWSKI L: Beyond Pain. New approaches to pain relief. New York Times Chicago Life Supplement (Sunday 23 November 1997):25/66–69.
   Web of Science ®Google Scholar
• ANONYMOUS: Obituary: John C. Liebeskind, 62, pioneer in the study of pain in humans. New York Times (Midwest Edition) (Saturday 20 September 1997):22.
   Google Scholar
• BROWNLEE S, SCHROF JM: The quality of mercy. US News World Report (March 17, 1997) 54–67. Popular overview of current trends in pain control.
   Google Scholar
• ZENZ M, WILLWEBER-STRUMPF A. Opiophobia and cancer pain in Europe. Lancet (1993) 341:1075–1076.
   PubMed Web of Science ®Google Scholar
• WOOLF CJ An overview of the mechanisms of hyperalgesia. Pulmon. Pharmacol. (1995) 8:161–167.
   PubMedGoogle Scholar
• ••Excellent overview of basic mechanisms of pain transmission.
   Google Scholar
• DRAY A, URBAN L, DICKENSON A: Pharmacology of chronic pain. Trends Pharmacol. Sci. (1994) 15:190–197.
   PubMed Web of Science ®Google Scholar
• ••Seminal update of recent progress in understanding the molecular basis of pain.
   Google Scholar
• DRAY A: Inflammatory mediators of pain. Br. J. Anaseth. (1995) 75:125–131.
   PubMed Web of Science ®Google Scholar
• Campbell JN (Ed.), IASP Press, Seattle, WA (1997):13–15.
   Google Scholar
• WOOLF CJ: Plasticity and pain. Presentation at the 27th Annual Meeting of the Society for Neuroscience Meeting. New Orleans, LA (27 October 1997).
   Google Scholar
• ••An outstanding presentation by one of the world's leading experts in pain researchsynthesising current knowledge of the molecular mechanisms contributing to the development of neuropathic pain.
   Google Scholar
• BENNETT GJ, XIE YK: A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain (1988) 33:87–107.
   PubMed Web of Science ®Google Scholar
• •Critical model for assessing neuropathic pain in animals.
   Google Scholar
• KIM SH, CHUNG JM: An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain (1992) 50:355–363.
   PubMed Web of Science ®Google Scholar
• •The Chung model of neuropathic pain that is widely used in pain research.
   Google Scholar
• COURTEIX C, BARDIN M, CHANTELAUZE C, LAVARENNE J, ESCHALIER A: Study of the sensitivity of the diabetes-induced pain model in rats to a range of analgesics. Pain (1994) 57:153–160.
   PubMed Web of Science ®Google Scholar
• NEUMANN S, DOUBELL TP, LESLIE T, WOOLF CJ: Inflammatory pain hypersensitivity mediated by phenotypic switch in myelinated primary sensory neurons. Nature (1996) 384:360–364.
   PubMed Web of Science ®Google Scholar
• ••An outstanding paper from Clifford Woolf's laboratory showing that pain can inducephenotypic changes in neurones in nociceptive pathways.
   Google Scholar
• MANN CC, PLUMMER ML: The Aspirin Wars. Knopf, New York (1991).
   Google Scholar
• ••A landmark book in the scientific and commercial aspects of the drug development andmarketing process. A "must read" for anyone interested in the evolution of the pharmaceutical industry and in the OTC market for pain control medications.
   Google Scholar
• CAMPBELL WI, KENDRICK RW: Pre-emptive analgesia using local anaesthesia: a study in bilaterally symmetrical surgery Br. J. Anaesth. (1997) 79:657–659
   PubMed Web of Science ®Google Scholar
• •Important concept of avoiding the deleterious effects of surgery on nociceptive pathways.
   Google Scholar
• Bowman WC, Fitzgerald JD, Taylor JB (Eds.), Ashley Publications Ltd., London (1996) 1:391–411.
   Google Scholar
• MARTINEZ C, WEIDMAN E: Methodological approach for the evaluation of adverse drug-attributed public health impacts. 11th International Conference on Pharmacoepidemiology. Montreal (30 August 1995).
   Google Scholar
• RODGER IW, CHAN C-C: Inducible cyclooxygenase (COX-2). In: Neuroinflammation: Mechanisms and Management. Wood PL (Ed.), Humana, Totowa, NJ (1998):355-371. 21.UCHITANI Y, SHI TJ, HAEGGSTROM JZ, SAMUELSSON B, KOEKELT T: Increased levels of cyclooxygenase-2 mRNA in the rat spinal cord after peripheral inflammation: an in situ hybridization study. NeuroReport (1997) 8:2949–2952.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ BD: COX-2 inhibitors; a safer class of drugs for inflammatory pain. Presentation at IBC Meeting Novel Targets in the Treatment of Pain. Washington, DC (6–7 October 1997).
   Google Scholar
• •Important verbal report on the Searle COX-2 inhibitor, celecoxib that reviewed emerging clinical data on efficacy and side-effect profile of this novel class of NSAID.
   Google Scholar
• MORRISON BW: The analgesic effect of selective COX-2 inhibitors. IBC Meeting Novel Targets in the Treatment of Pain. Washington, DC (6–7 October 1997).
   Google Scholar
• •Verbal report from Merck on MK-966, the most selective COX-2 inhibitor (> 8000-fold) reported to date.
   Google Scholar
• GRISWOLD DE, RUFFOLO RR, POSTE G, TORPHY TJ: Re-classification of NSAIDs. Trends Pharmacol. Sci. (1997) 18:311.
   PubMed Web of Science ®Google Scholar
• CLISSOLD SP: Paracetamol and phenacetin. Drugs (1986) (Suppl. 4):46–59.
   PubMed Web of Science ®Google Scholar
• CHERNY NI: Opioid analgesics. Comparative features and prescribing guidelines. Drugs (1996) 51:713–717.
   PubMed Web of Science ®Google Scholar
• Hardman JG, Limbird, LE, Molinoff PB, Ruddon RW, Gilman AG (Eds.), McGraw Hill, New York (1996):521–555.
   Google Scholar
• REINSCHEID RK, NOTHACKER H-P, BOURSON A, et al Orphanin FQ: a neuropeptide that activates an opioid-like G-protein coupled receptor. Science (1995) 270:792–794.
   PubMed Web of Science ®Google Scholar
• SHARP B, YAKSH T: Pain killers of the immune system. Nature Med. (1997) 3:831–832.
   PubMed Web of Science ®Google Scholar
• COZZENS SE: Social Control and Multiple Discovery in Science. The Opiate Receptor Case. SUNY Press, Albany, New York (1989).
   Google Scholar
• ••An important sociological case history that discusses aspects of the discovery of the opioidreceptor and the enkephalins.
   Google Scholar
• Campbell JN (Ed.), IASP Press, Seattle, WA (1996) 559–566.
   Google Scholar
• KORZENIEWSKA-RYBICKA I, PLAZNIK A: Analgesic effect of antidepressant drugs. Pharmacol. Biochem. Behav. (1998) 59:331–338.
   PubMed Web of Science ®Google Scholar
• FLACKE JW, BLOOR BC, FLACKE WE, et al Reduced narcotic requirement by clonidine with improved hemodynamic and adrenergic stability in patients undergoing coronary bypass surgery. Anesthesiology (1987) 67:11–19.
   PubMed Web of Science ®Google Scholar
• GEE NS, BROWN JP, DISSANAYAKE VUK, et al The novel anticonvulsant drug, gabapentin (Neurontin), binds to the oc2ö subunit of a calcium channel. J. Biol. Chem. (1996) 271:5768–5776.
   PubMed Web of Science ®Google Scholar
• CHAPLAN SR, CALCUTT NA, SCOTT BP, ZEITLIN A, YAKSH TL: Stereospecific effects of mexiletine in experimental allodynia in the rat. Abstract presented at the IBC Meeting Novel Targets in the Treatment of Pain. Washington, DC (6–7 October 1997).
   Google Scholar
• ZIPKIN I: Big Enbrel hit for Immunex. BioCentury Extra (1997) 5(83):1–2.
   Google Scholar
• BRIEBART W, ROSENFELD BD, PASSIK T, et al The undertreatment of pain in ambulatory AIDS patients. Pain (1996) 65:243–249.
   PubMed Web of Science ®Google Scholar
• MAYER EA, GEBHART GR: Basic and clinical aspects of visceral hyperalgesia. Gastroenterology (1994) 107:271–293.
   PubMed Web of Science ®Google Scholar
• BUENO L, FIORAMONTI J, DELVAUX M, FREXINOS J: Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. Gastroenterology (1997) 112:1714–1743.
   PubMed Web of Science ®Google Scholar
• WALLACE JL, ELLIOTT SN, DEL SOLDATO P, et al Gastrointestinal sparing anti-inflammatory drugs: the development of nitric oxide- releasing NSAIDs. Drug Dev. Res. (In press).
   Google Scholar
• KRISTENSEN JD, SVENSSON B, GORDH T: The NMDA receptor antagonist CPP abolishes neurogenic wind-up pain after intrathecal administration in humans. Pain (1992) 51:249–253.
   PubMed Web of Science ®Google Scholar
• BADIO B, GARRAFFO HM, SPANDE TF, DALY JW: Epibatidine: discovery and definition as a potent analgesic and nicotininc agonist. Med. Chem. Res. (1994) 4:440–448.
   Google Scholar
• ••An overview of the discovery by John Daly's group at the NIH of the frog analgesic, epibatidine, an alkaloid identified as a nicotinic receptor agonist and found to be more potent than the opioids as a analgesic without the potential for respiratory depression, constipation and addiction associated with morphine and its congeners. This led to considerable interest in the nicotinic receptor as a target for novel analgesics. Unfortunately, epibatidine had significant side-effect liabilities due its lack of receptor subtype selectivity. While epibatidine was discovered in the frog in quantities less than 1 mg, initial attempts to produce more compound by breeding frogs in captivity were unsuccessful suggesting that the alkaloid was extracted by the frog from insects or plants in its natural environment. The discovery of epibatidine reinforces the value of natural product chemistry approaches to drug discovery and cautions overdependence on combinatorial chemistry libraries as the source of novel receptor ligands.
   Google Scholar
• BANNON AW, DECKER MW, HOLLADAY MW, et al Broad spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science (1998) 279:77–81.
   PubMed Web of Science ®Google Scholar
• ••The first full paper on the nicotinic receptor modulator, ABT-594 from the Abbott group thathas similar analgesic potency to epibatidine with less activity on ganglionic and neuromuscular nicotinic receptor subtypes. The compound is currently in Phase I clinical trials.
   Google Scholar
• GHELARDININ G, GALEOTTI N, BARLOCCO D, BARTOLINI A: Antinocicpetive profile of the new nicotinic agonist DBO-83. Drug Dev. Res. (1997) 40:251–258.
   Web of Science ®Google Scholar
• GHELARDINI G, GALEOTTI N, GUALTIERI F, et al Antinociceptive property of the nicotinic agonist AG-4 in rodents. Drug Dev. Res. (1997) 41:1–9.
   Web of Science ®Google Scholar
• SHANNON HE, SHEARDOWN MJ, BYMASTER FP, et al Pharmacology of butylthio [2.2.2.] (LY297802/NNC11-1053): a novel analgesic with mixed muscarinic receptor agonist and antagonist activity. J. Pharmacol. Exp. Ther. (1997) 281:884–894.
   PubMed Web of Science ®Google Scholar
• •A muscarinic analgesic discovered by the Novo-Nordisk group that is being co-developed with Lilly. It is rumoured that the compound has been dropped due to GI side-effect liabilities that are typically associated with muscarinic receptor activation and which has plagued this area from a drug discovery viewpoint.
   Google Scholar
• GHELARDINI G, GALEOTTI N, GUALTIERI F, et al Antinociceptive profile of 3-a-tropanyl-(2-C1)- acid phenoxybutyrate (SM-21): a novel analgesic with a presynaptic cholinergic mechanism of action. J. Pharmacol. Exp. Ther. (1997) 282:430–439.
   PubMed Web of Science ®Google Scholar
• GHELARDINI G, GALEOTTI N, FANTETTI L, et al Central muscarinic antinociception induced by ET-142 and SS-20 in rodents. Drug Dev. Res. (1997) 42:26–34.
   Web of Science ®Google Scholar
• BURNSTOCK G: A unifying purinergic hypothesis for the initiation of pain. Lancet (1996) 347:1604–1605.
   PubMed Web of Science ®Google Scholar
• ••A concise, erudite overview of the role of adenosine and ATP in nociceptive processing.
   Google Scholar
• Jacobson KA, Jarvis MF (Eds)., Wiley-Liss, New York (1997) :495–513.
   Google Scholar
• SOLLEVI A: Adenosine for pain control. Acta Anaesth. Scand. (1997) 135–236.
   Web of Science ®Google Scholar
• KARLSTEN R, GORDH T: An A1-selective adenosine agonist abolishes allodynia elicited by vibration and touch after intrathecal injection. Anesth. Analg. (1995) 80:844–847.
   PubMed Web of Science ®Google Scholar
• BELLFRAGE M, SOLLEVI A, SEGERDAHL M, et al Systemic adenosine infusion alleviates spontaneous and stimulus evoked pain in patients with peripheral neuropathic pain. Anesth. Analg. (1995) 81:713–717.
   PubMed Web of Science ®Google Scholar
• ••A report of the use of adenosine for the treatment of neuropathic pain at doses that are without effect on the cardiovascular system.
   Google Scholar
• SEGERDAHL M, IRESTEDT L, SOLLEVI A: Antinociceptive effect of perioperative adenosine infusion in abdominal hysterectomy. Acta Anesth. Scand. (1997) 41:180–185.
   Web of Science ®Google Scholar
• Jacobson KA, Jarvis MF (Eds.), Wiley-Liss, New York (1997) 471–493.
   Google Scholar
• ••An overview of pioneering work in the use of ATP as an anaesthetic adjuvant.
   Google Scholar
• WANG B, TANG J, WHITE PF, et al The effects of GP683, an adenosine kinase inhibitor, on the desflurane anesthetic requirement in dogs. Anesth. Analg. (1997) 85:675–680.
   PubMed Web of Science ®Google Scholar
• ENGLER RA: Adenosine: the signal of life Circulation (1991) 84:951–954.
   PubMed Web of Science ®Google Scholar
• FIRESTEIN GS: Anti-inflammatory effects of adenosine kinase inhibitors in acute and chronic inflammation. Drug Dev Res. (1996) 39:371–376.
   Web of Science ®Google Scholar
• ••An overview of the author's work demonstrating that adenosine is a potent, broad spectrumanti-inflammatory agent that may also have disease modifying potential.
   Google Scholar
• CRONSTEIN BN, NAIME D, FIRESTEIN G: The antiinflammatory effects of an adenosine kinase inhibitor are mediated by adenosine. Arth. Rheum. (1995) 38:1040–1045.
   PubMed Web of Science ®Google Scholar
• Jacobson KA, Jarvis MF (Eds.), Wiley-Liss, NY (1997) :285–299.
   Google Scholar
• GU JG, MACDERMOTT AB: Activation of ATP P2X receptors elicits glutamate release from sensory neuron synapses. Nature (1997) 389:749–753.
   PubMed Web of Science ®Google Scholar
• BLAND-WARD PA, HUMPHREY PPA: Acute nociception mediated by hindpaw P2X receptor activation in the rat. Br. J. Pharmacol. 122:365–371.
   PubMed Web of Science ®Google Scholar
• CHEN CC, AKOPIAN AN, SIVILOTTI L, et al A P2x purinoceptor expressed by a subset of sensory neurons. Nature (1995) 377:428–431.
   PubMed Web of Science ®Google Scholar
• KASSOTAKIS LC, NAVAKOVIC SD, OGLESBY IB, FORD APDW, HUNTER JC: Immunocytochemical localization of P2X3 receptors in normal and neuropathic rats. ASPET/BPS Meeting. San Diego, CA. Abstract 191.
   Google Scholar
• ••Abstract from the Roche group showing that chronic pain can upregulate P2X3 receptors.
   Google Scholar
• MILLS SG: Recent advances in neurokinin receptor antagonists. Ann. Rep. Med. Chem. (1997) 32:51–60.
   Web of Science ®Google Scholar
• ••Thorough overview of recent developments in neurokinin receptor research.
   Google Scholar
• JACK DB: Wider use of cannabinoids Drug News Perspect. (1997) 10:440–442.
   Google Scholar
• SZALLASI A: Perspectives on vanilloids in clinical practice. Drug News Perspect. (1997) 10:522–527.
   Web of Science ®Google Scholar
• •A timely review of the analgesic/anti-inflammatory potential of vanilloids.
   Google Scholar
• CATERINA MJ, SCHUMACHER M, TOMINAGA M, et al The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature (1997) 389:816–824.
   PubMed Web of Science ®Google Scholar
• ••An elegant paper describing the cloning of the capsaicin receptor and the properties of theexpressed clone.
   Google Scholar
• BADGER AM, LEE JC: Advances in antiarthritic therapeutics. Drug Disc. Today (1997) 2:427–434.
   Web of Science ®Google Scholar
• BADGER AM: J. Pharmacol. Exp. Ther. (1996) 279:1453–1461.
   Google Scholar
• ALTMAN LK Study on using magnets to treat pain surprises skeptics. New York Times (Midwest Edition). (9 December 1997):B11.
   Google Scholar
• •An interesting account in the popular press of the potential use of magnetic fields in the treatment of pain.
   Google Scholar
• SCHIFFMAN SN, PEDRAZZINI T, EL YACOUBI M, et al Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2. receptor. Nature (1997) 388:674–678.
   PubMed Web of Science ®Google Scholar
• MURATA T, USHIKUBI F, MATSUOKA T, et al Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature (1997) 388:678–682.
   PubMed Web of Science ®Google Scholar
• ••One of several recent papers using knockout mice to determine the role of a particularreceptor in pain processing.
   Google Scholar
• MALMBERG AB, CHEN C, TONEGAWA S, BUSBAUM Al: Preserved acute pain and reduced neuropathic pain in mice lacking PKCy. Science (1997) 278:279–283.
   PubMed Web of Science ®Google Scholar
• LAKHLANI PP, MACMILLAN LB, GUO TZ, et al.: Substitution of a mutant an-adrenergic receptor via "hit and run" gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic - sparing responses in vivo. Proc. Natl. Acad. Sci. USA (1997) 94:9950–9955.
   PubMed Web of Science ®Google Scholar
• KING B, BURNSTOCK G: Changes in the pH in the immediate milieu of P2 receptors change their pharmacological properties. Br. J. Pharmacol. 118.
   Google Scholar
• COOK SP,VULCHANOVA L, HARGREAVES KM, ELDER, MCCLESKY EW: Distinct ATP receptors on pain-sensing and stretch-sensing neurons. Nature (1997) 387:505–508.
   PubMed Web of Science ®Google Scholar